SORENTO™: Subcutaneous Octreotide for GEP-NETs (CAM2029)

SORENTO™ - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETs

CLINICALTRIALS.GOV IDENTIFIER: NCT05050942

DRUG/TREATMENT: CAM2029, octreotide LAR, lanreotide ATG

PHASE: 3

STATUS: Recruiting

SPONSOR:  Camurus AB

Dr. Simron Singh Discusses the SORENTO™ Trial

DESCRIPTION:

Camurus is sponsoring a phase 3 study to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Camurus AB 

EMAIL: medicalinfo@camurus.com

PHONE: +46 46 286 57 30

Principal Investigator:

Simron Singh, MD, MPH

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada